Plain-English translation of NCT04576429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are studying how the immune system changes when melanoma patients receive immunotherapy with medications like pembrolizumab or nivolumab. By collecting blood samples and tracking immune markers over time, they hope to identify which patients will have the best outcomes and which ones might need different treatment approaches.
Immunotherapy works well for some melanoma patients but not others, and doctors don't yet have reliable ways to predict who will respond best. This study aims to discover immune system patterns that could help predict treatment success and guide future care decisions.
You likely qualify if…
You likely don't qualify if…
You will visit the study center before starting your immunotherapy and then at regular tumor check-ups (up to 12 months total). At each visit, researchers will take blood samples to analyze your immune system markers. If you're receiving additional radiotherapy, you'll have extra visits scheduled around that treatment. The study involves blood draws only — no additional medications or procedures beyond your standard melanoma care.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France